Financial Tearsheet
Company Overview
ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
Recent Financial News
IR Contacts
| LHA Investor Relations |
|
Kim Sutton Golodetz
|
Stock Performance
| Today's Open | 2.55 |
| Volume | 2.65 million |
| Day Range | 2.46 - 2.69 |
| 52 Week Range | 0.60 - 2.99 |
| Bid/Ask | 2.61 / 2.62 |
| Bid/Ask Size | 1,300 X 2,700 |
| Previous Close | 2.50 |
| Market Cap | 88.81 million |
| Shares Outstanding | 33.64 million |
| Dividend/Yield | 0.00 / 0.00% |
| EPS (TTM) | -1.830400 |
| P/E Ratio (TTM) | N/A |
